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Common variable immunodeﬁciency is the most common form of symptomatic primary antibody failure in adults and children.
Replacement immunoglobulin is the standard treatment of these patients. By using a diﬀerential proteomic approach based on
2D-DIGE, we examined serum samples from normal donors and from matched, naive, and immunoglobulin-treated patients.
The results highlighted regulated expression of serum proteins in naive patients. Among the identiﬁed proteins, clusterin/ApoJ
serum levels were lower in naive patients, compared to normalsubjects. This ﬁnding was validated in a wider collection of samples
from newly enrolled patients. The establishment of a cellular system, based on a human hepatocyte cell line HuH7, allowed to
ascertain a potential role in the regulation of CLU gene expression by immunoglobulins.
1.Introduction
Common variable immunodeﬁciency (CVID), the most fre-
quentsymptomatic primary immunodeﬁciency,is a rare dis-
ease, with a prevalence estimated to be between 1:25,000 to
1:50,000 [1]; unlike many genetic immune defects, the vast
majority of patients with CVID are adults between the ages
of 20 and 40 years, although many are found outside this age
range [2]. CVID is characterized by signiﬁcantly decreased
levels of IgG, IgA, and/or IgM, with poor or absent antibody
production, which results in reduction of immune defense
[3]. Patients with CVID have an increased susceptibility to
infections of the respiratory system and the gastrointestinal
tract. These infections can cause irreversible changes of the
aﬀected organs, including bronchiectasis, chronic obstruc-
tive pulmonary disease, intestinal mucosal atrophy, chronic
diarrhea, and protein-wasting enteropathy [2–5]. The clini-
cal course of patients with CVID may also be complicated by
a wide spectrum ofautoimmune diseases, includingsystemic
immune (e.g., systemic lupus erythematosus or rheumatoid
arthritis) or organ-speciﬁc disorders (such as thyroiditis, di-
abetes mellitus type I, vitiligo)[ 6–14].
The incidence of malignancy appears overall increased
in CVID, occurring in up to 15% of patients [15]. Increase
in cancer is found most attributable to stomach cancer and
non-Hodgkin lymphoma [2, 16–21].
The primary treatment of CVID is replacement of anti-
body, achieved by either an intravenous or subcutaneous
routeofIg,usuallyindosesof400to600mg/kgbody weight/
month [22, 23]. Several gene mutations, associated with ap-
proximately 10% of CVID have been recently identiﬁed.
The aﬀected genes include ICOS (inducible costimulator2 Journal of Biomedicine and Biotechnology
molecules) [24], CD19 [25, 26], TNFRSF13C (encoding for
BAFF-R: B-cell activating factor of the TNF family receptor)
[27],andTNFRSF13B,(encodingforTACI:trans-membrane
activator and calcium modulating cyclophilin ligand inter-
actor) [28]. All the proteins encoded by these genes are
essential for the implementation of proper and eﬀective
antibody responses; in fact, they are regulatory molecules
variously expressed on B and T lymphocytes, involved at
diﬀerent levels along the route of maturation and activation
of B lymphocytes. The complexity of the immune system
and its molecular repertoire predicts that additional genetic
defects underlying CVID could be identiﬁed, which may
partly account for the clinical phenotypic heterogeneity of
these patients.
One of the most challenging applications of expression
proteomics is the quantitative analysis of serum proteins for
comparative purposes; availability of serum collections from
patients at diﬀerent steps of disease progression and ther-
apeutic treatments can lead to the discovery of useful bio-
markers for diagnosis, evaluation of therapeutic eﬃcacy, and
for the clariﬁcation of the mechanisms underlying complex
diseases [29]. In this paper, we describe the application of
2D-DIGE(twodimension:diﬀerentialingelelectrophoresis)
technology to CVID. On one hand, we compared the serum
proteome in a small cohort of newly enrolled, naive patients,
totheproteomeofhealthy individuals,with theaimtodetect
protein expression diﬀerences. Secondly, we compared the
serum protein proﬁles of patients at diagnosis with those
occurring one year after intravenous Ig treatment (IVIg),
to assess the possible modulation made by the therapy.
Clusterin/ApoJ, encoded by the CLU gene, was downregu-
lated in naive patients compared to normal subjects. Serum
Clusterin/ApoJ levels were evaluated by western blotting on
a widerset ofsamples, conﬁrming theactual downregulation
of this protein in the serum of naive patients. Incubation of
the hepatocyte cell line HuH7 with human polyclonal IgG
increased the constitutive expression of CLU mRNA.
2.Materialsand Methods
2.1. Patients. Patients enrolled for this study were diagnosed
and are currently treated at the Center for Diagnosis and
Treatment of Adult Primary Immunodeﬁciency, Division
of Clinical Immunology and Allergy of the University of
Naples “Federico II”. Diagnosis of CVID was performed
according to the diagnostic criteria established by the Euro-
pean Society for Immunodeﬁciencies (ESID). 15 patients
were enrolled (7 males and 8 females), with an average
age of 30 at diagnosis. Three naive patients enrolled in the
study contributedwith serum samples for2D-DIGEanalyses
at the time of diagnosis (N1–N3, Table 1)a n do n ey e a r
after the beginning of IVIg therapy (I1–I3). Serum samples
of 6 naive patients, which were diagnosed with CVID at
later times during the collection phase, were characterized
by western blot analysis (N4–N9, Table 2). Six additional
patients (I4–I9), already receiving IVIg treatment for at least
ﬁve years, were also tested by western blot analysis. Serum
samples from 12 normal donors (C1–C12, 5 male, 7 female;
averageage29)wereusedtogeneratetwopoolsfor2D-DIGE
analysis (P1 and P2, Table 1); six randomly selected samples
from the cohort of normal donors were also individually
used for western blot analysis. The main clinical features of
the patients are reported in Tables 1 and 2.
2.2. 2D-DIGE Analysis. For 2D-DIGE analysis, serum sam-
ples were subjected to albumin and immunoglobulin deple-
tion on Q-Proteome Albumin/IgG columns (Qiagen), as
suggested by the manufacturer. Protein concentration of
the albumin/IgG-depleted sera was determined according to
Bradford method (BioRad protein assay, BioRad). Samples
were ﬁnally precipitated in acetone/methanol (8:1, v/v) for
16h, at −20◦C and recovered by centrifugation at 16,000
×gf o r3 0 m i n ,a t4 ◦C. Proteins were solubilised in 7M
urea, 2M thiourea, 4% CHAPS, 30mM Tris-HCl. Pro-
tein concentrations were redetermined using the Bradford
method (Bio-Rad). Before labelling, the pH of the samples
was adjusted to pH 8.5 with HCl solutions. Each labelling
reaction was performed with 50μgo ft h ep r o t e i ne x t r a c t s ,
in a 10μl volume, in the presence of 400pmol of Cy2-,
Cy3-, or Cy5-dyes (minimal labelling dyes, GE Healthcare).
Two pools of 6 serum samples from normal donors were
generated from a collection of 12 samples (C1 to C12); the
two pools, P1 and P2 (Table 1), were individually labelled
with Cy3 and Cy5 dye, respectively. A dye-swapping strategy
was used to label serum samples from the three enrolled
patients (Pt. 1, Pt. 2, and Pt. 3); accordingly, two sera
from naive patients were labelled with Cy3, while the third
was labelled with Cy5; in a complementary manner, two
sera from IVIg-treated patients were labelled with Cy5, and
the third was labelled with Cy3. Four mixtures of the 8
samples (50μg each) were labelled with Cy2 dye, as the
internal standard required by the 2D-DIGE protocol. The
labelling reactions were performed in the dark for 30min,
at 0◦C and were stopped by addition of 1mM lysine. The
four sample mixtures, including appropriate Cy3- and Cy5-
labeled pairs and a Cy2-labeled control, were generated and
supplemented with 1% IPG buﬀer (v/v), pH 3–10 NL (GE
Healthcare), 1.4% DeStreak reagent (v/v) (GE Healthcare),
and 0.2% DTT (w/v) to a ﬁnal volume of 450μli n7 M
urea, 2M thiourea, and 4% CHAPS. The mixtures (150μg
of total protein content) were used for passive hydration
of immobilized pH gradient IPG gel strips (24cm, pH 3–
10NL) for 16h, at 20◦C. Isoelectric focusing (IEF) was
carried out with an IPGphor II apparatus (GE Healthcare)
up to 75,000V/h at 20◦C (current limit set to 50μAp e r
strip).Thestripswereequilibratedin6Murea,2%SDS,20%
glycerol, and 0.375M Tris-HCl (pH 8.8), for 15min, in the
dark, in the presence of 0.5% DTT (w/v), and then in the
presence of 4.5% iodacetamide (w/v) in the same buﬀer, for
additional 15min. Equilibrated IPG strips were transferred
onto 12% polyacrylamide gels, within low-ﬂuorescence
glass plates (ETTAN-DALT 6 system, GE Healthcare). The
second-dimensionSDS-PAGEwasperformedusingaPeltier-
cooled DALT II electrophoresis unit (GE Healthcare) at
1.5W/gel for 16h. Gels were scanned with a Typhoon 9400
variable mode imager (GE Healthcare) using appropriateJournal of Biomedicine and Biotechnology 3
Table 1: Clinical and laboratory data of healthy donors (C1–C12) and patients (Pt.1–Pt.3) contributing to serum samples for 2D-DIGE
analysis.
ID Sex Serum sample Age
(years)
Total protein level
(g/dL)
Ig level (mg/dL) ERS
(mm/1sth)
CRP
(mg/dL)
Observed
complications IgG IgA IgM
C1 M 32 7 1400 250 150 14 0.35 —
C2 F 24 6.5 1100 200 80 14 0.33 —
C3 M
P1 33 7 1200 180 85 18 0.33 —
C4 M 29 6.8 1180 300 98 11 0.36 —
C5 F 30 6.9 1110 100 100 70 . 4 —
C6 M 32 7.2 1300 180 110 70 . 3 5 —
C7 F 27 7 1280 270 70 40 . 3 0 —
C8 F 31 6.6 900 260 90 20 0.5 —
C9 M
P2 30 6.8 980 360 180 20 . 5 —
C10 F 28 7.2 1160 220 150 40 . 3 5 —
C11 F 26 6.8 990 230 90 20 . 3 5 —
C12 F 27 7 1200 250 90 16 0.30 —
Pt. 1 M N1 33 6.2 7 6.1 10.5 9 <0.31 R, A
I1 34 7.5 400 6.1 10 20 0.5 R, A
Pt. 2 F N2 12 5.9 171 6.1 4.1 71 R
I2 13 6.5 350 6.1 6 14 0.5 R
Pt. 3 M N3 59 6.3 273 13.9 38 18 1.79 R, GI
I3 60 7 380 15 50 24 1.4 R, GI
ESR: erythrocyte sedimentation rate; CRP: C-reactive protein; R: respiratory tract infections; GI: gastrointestinal tract infections; A: autoimmunity.
Table 2: Clinical and laboratory data of naive (N4–N9) and IVIg-treated patients (I4–I9) contributing to serum samples for western blot
determinations of serum clusterin levels.
ID Sex Age
(years)
Total protein level
(g/dL)
Ig level (mg/dL) ESR
(mm/1sth)
CRP
(mg/dL)
Observed
complications IgG IgA IgM
N4 M 33 6.9 288 6.2 7.3 10 <0.31 R
N5 F 44 5.9 235 12.2 43.5 28 4.59 R, GI
N6 F 30 5.6 70 4 . 5 27 7.54 R, GI, M
N7 F 38 5.7 230 12.1 43.4 26 4.50 R, GI
N8 M 30 6.2 69 <6.2 <4.5 4 <0.31 R, GI, A
N9 F 13 6.6 253 6.2 8.2 80 . 7 5 R
I4 M 13 7.4 418 6.1 13.3 13 0.35 R, GI
I5 M 20 6.6 1000 13.9 54 12 0.31 R, GI
I6 F 39 7.1 910 5.8 15 10 0.31 R, GI
I7 F 19 6.4 700 6.1 10.5 70 . 3 3 R
I8 M 47 7.2 600 63 4.1 80 . 3 1 R , G I , A
I9 F 17 6.7 481 6.9 4.1 10 0.31 R, GI
ESR: erythrocyte sedimentation rate; CRP: C-reactive protein; R: respiratory tract infections; GI: gastrointestinal tract infections; A: autoimmunity; M:
malignancy.
excitation/emission wavelengths for Cy2 (488/520nm), Cy3
(532/580nm), and Cy5 (633/670nm). Images were captured
in the Image-Quant software (GE Healthcare) and analyzed
using the DeCyder 6.0 software (GE Healthcare). A DeCyder
diﬀerential in-gel-analysis (DIA) module was used for spot
detection and pairwise comparison of each sample (Cy3
and Cy5) to the Cy2 mixed standard present in each gel.
The DeCyderbiologicalvariation analysis (BVA)modulewas
then used to simultaneously match all of the protein-spot
mapsfromthegels,andtocalculateaverageabundanceratios
and statistical parameters across triplicate samples (Student’s
t-test).
For preparative protein separations, 600μg of unlabeled
protein samples from albumin/IgG depleted, pooled serum
samples from normal donors and the three CVID patients
were used to passively hydrate 24cm strips for ﬁrst dimen-
sion (pH 3–10 NL IPG strips, GE Healthcare). The ﬁrst
and second dimension runs were carried out as previously4 Journal of Biomedicine and Biotechnology
described for the analytical separations. After 2-DE, gels
were ﬁxed and stained with SyproRuby ﬂuorescent stain
(invitrogen). After spot matching with the master gel from
the analytical step in the BVA module of DeCyder software,
a pick list was generated for spot picking by a robotic picker
(Ettan spot picker, GE Healthcare).
2.3. Protein Identiﬁcation and Bioinformatic Analysis. Iso-
lated spots were minced and washed with water. Proteins
were reduced,S-alkylated,and in-gel digestedwithtrypsin, as
previously reported [30]. Digest samples were desalted and
concentrated on microC18 ZipTips (Millipore Corp., Bed-
ford, MA) using acetonitrile as eluent before MALDI-TOF-
MS analysis. Peptide mixtures were loaded on the MALDI
target together with α-cyano-4-hydroxycinnamic acid as
matrix, using the dried droplet technique. Samples were
analyzed with a Voyager-DE PRO spectrometer (Applied
Biosystems, Framingham MA, USA). Spectra were acquired
in reﬂectron mode; internal mass calibration was performed
with peptides deriving from trypsin autoproteolysis. Pro-
Found software package was used to identify spots from
independent nonredundant human sequence databases by
peptide mass ﬁngerprint experiments [31]. Candidates with
ProFound Est’d Z scores >1.8 (corresponding to P<0.05
for a signiﬁcant identiﬁcation) were further evaluated by the
comparison with molecular mass and pI experimental values
obtained from 2-DE. The occurrence of protein mixtures
was excluded by sequential searches for additional protein
components using unmatched peptide masses. Protein iden-
tiﬁcation was conﬁrmed by performing PSD fragment ion
spectral analysis of the most abundant mass signal within
each MALDI-TOF-MS spectrum, as previously reported
[32].
Gene ontology classiﬁcation of the identiﬁed proteins
was performed through the web-accessible DAVID (v 6.7)
annotation system (http://david.abcc.ncifcrf.gov/home.jsp)
[33, 34]. Brieﬂy, the identiﬁed proteins were converted into
RefSeq-protein identiﬁers through the DAVID Gene ID con-
version tool; the new list was then submitted to functional
annotation clustering.
2.4.Western BlottingAnalysis. Western blotanalysis was used
tovalidatediﬀerentialexpressiondataobtainedbyproteomic
analysis. Equal volumes of diluted serum samples, corre-
sponding to 0.5μLo fw h o l es e r u mf r o m6n o r m a ld o n o r s ,
6 newly enrolled naive, CVID patients, and 6 inpatients
undergoing IVIg replacement therapy since >5y e a r sw e r e
separated on 10% polyacrylamide gels by SDS-PAGE and
then blotted on PVDF membranes (GE Healthcare). Filters
were blocked in PBS containing 5% nonfat dry milk and
incubated with a 1:250 dilution of the polyclonal, anti-
clusterin primary antibody H-330 (Santa Cruz Biotech-
nology), for 2h. Anti-rabbit IgG horseradish peroxidase
conjugated was used as secondary antibody; bands were
visualised by ECL kit (GE Healthcare) on a Chemi Doc
XRS apparatus (BioRad). Filters were ﬁnally probed with the
mouse monoclonal anti-ApoH antibody 1D2 (Santa Cruz
Biotechnology). Chemiluminescent signals were quantitated
through the Quantity One 1-D Analysis Software (BioRad);
background signals were subtracted from each value. The
net chemiluminescence value due to anticlusterin antibody
fromeachsamplewasnormalizedtothecorrespondingvalue
of ApoH signal. The normal serum sample with highest
normalized clusterin expression was arbitrary set to 1, and
the normalized clusterin expression of all remaining samples
was referred to this value. The t-test method was used for
statistical evaluations of relative clusterin levels among the
control, naive, and IVIg-treated groups.
2.5. Cell Cultures and Real-Time PCR Analysis. HuH7 cells
were cultured in DulbeccoModiﬁed Eagle’s Medium supple-
mented with 10% foetal bovine serum, 1% penicillin/strep-
tomycin, 2mM L-glutamine (complete medium) at 37◦C,
under 5% CO2. Cultures were gradually adapted to serum-
free medium(Opti-MEM,Invitrogen)bysequentialpassages
in media with increasing concentration of Opti-MEM (1:1,
1:2, 1:3 complete:serum-free medium, resp.), then to
100% serum-free medium. Cells were ﬁnally cultured for
at least three additional passages in serum-free medium,
then evaluated for proliferation by standard growth curves.
Adapted HuH7 cells were transferred to 6-well plates and
grown in Opti-MEM, then treated with 0.5% (w/v) bovine
serum albumin (Sigma-Aldrich) or human polyclonal IgG
(Ig VENA, Kedrion Biopharmaceuticals) for 4h. Total RNA
was extracted from triplicate cultures from each treatment
with Trizol reagent (Invitrogen). For reverse transcription
of DNase-treated total RNA samples (1μgp e rs a m p l e ) ,t h e
SuperScript VILO cDNAsynthesis kit (Invitrogen) was used,
with pdN6 primers. Quantitative real-time PCR was per-
formed on a 7500 Real-Time PCR System (Applied Biosys-
tems) using 10μL of EXPRESS SYBR GreenER qPCR Super-
MixwithPremixedROX(Invitrogen),10μMeachofforwar d
and reverse primers and 10μL of diluted cDNA (1:200).
The oligonucleotide primers were designed by the Primer
Express software (Applied Biosystems); their sequences were
the following: CLU forward, 5 -CGCTGACCGAGGCGT-
G-3 ; CLU reverse, 5 -CCACTCTCCCAGGTCAGCAG-
3 ; APOH forward, 5 -TGCTATTGCAGGACGGACCT-
3 ; APOH reverse, 5 -GGCTCATAGAATGTTTTTAAC-
GGG-3 ; ACTB forward, 5 -CGTGCTGCTGACCGAGG-3 ,
ACTB reverse, 5 -GAAGGTCTCAAACATGATCT-3 .F o r
calculation of relative mRNA expression, ACTB (β-actin)
transcripts were used as the reference mRNA; data analysis
was carried out according to the ΔΔCt method [35, 36].
3.Resultsand Discussion
3.1. Identiﬁcation of SerumProteins Diﬀerentially Expressed in
CVID. To evaluate distinctive signatures of serum proteins
in CVID, we analyzed three available naive patients (Pt.
1–3, Table 1). The corresponding serum samples, taken at
the time of diagnosis, were used in 2D-DIGE experiments
and compared to pooled serum samples of normal donors
(P1 and P2). Serum samples of the three patients were also
taken after one year of therapy with IVIg, to evaluate the
eﬀects of replacement therapy on serum protein expression.Journal of Biomedicine and Biotechnology 5
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Figure 1: 2-DE map of diﬀerentially expressed proteins in CVID. The ﬁgure shows the position on the master (a) and on the preparative
(b) gels of the 27 deregulated spots, as revealed by the comparison of serum samples from normal and CVID patients. In (a), the spots are
surrounded by a white border; matched spots within the preparative gel (b) are highlighted by a yellow circle, also indicating the picking
surface for the robotic spot picker. The representative image reported in (a) shows to the Cy2-labelled proteins on the scanned master gel;
protein spots in (b) were visualized by Sypro Ruby ﬂuorescent staining.
Table 1 summarizes the clinical and laboratory data of the
three patients at diagnosis (N1, N2, and N3) and follow-
ing one year from replacement therapy with intravenous
immunoglobulins (I1, I2, and I3). To obtain partial enrich-
ment of serum proteins, all the samples were subjected
to aﬃnity chromatography for depletion of albumin and
immunoglobulins. The 2D-DIGE analysis on the depleted
samples allowed to identify statistically signiﬁcant variations
between the diﬀerent conditions. Figure 1 shows the image
of the gel, selected as the “Master gel”, for spot matching
among the4analytical gels(run forthequantitativeanalysis)
Figure 1(a), and the preparative gel (run for spot picking
and identiﬁcation) Figure 1(b). Namely, 27 protein spots,
reported in Figure 1(a), showed signiﬁcant relative expres-
sion ratios in at least one out of the three possible com-
parisons (i.e., naive versus normal donors, naive versus IVIg
treatment, IVIg treatment versus normal donors, Table 3).
To identify the diﬀerentially expressed proteins, the spots of
interest were excised from the preparative gel (Figure 1(b)),
digested with trypsin and subjected to MALDI-TOF-MS
analysis. Table 3 shows the details of each protein spot iden-
tiﬁcation. The occurrence of multiple close spots identiﬁed
as the same protein species, occurring with the horizontal
train’s aspect typical of glycosylated serum proteins, led to
the ﬁnal recognition of 9 diﬀerentially expressed polypeptide
entries (Table 3).
3.2.SerumProteinExpression inCVID. Amongtheidentiﬁed
proteins, gene ontology classiﬁcation highlighted common
participation of the genes encoding alpha-2-macroglobulin,
clusterin, complement factor B, ﬁcolin-3, α-1 antitryp-
sin to inﬂammatory responses (GOTERM BP ALL, “acute
inﬂammatory response”, P = 1.5E − 7), with genes coding
for α1-antitrypsin, ceruloplasmin, complement factor B,and
haptoglobin being also described as involved in acute-phase
response (SP PIR KEYWORDS,“acutephase”,P = 1.7E−7).
Most of the spots corresponding to these proteins were
upregulated in naive patients, compared to healthy controls
(Table 3). Moreover, a quantitative comparison of their
relative levels showed less pronounced up-regulation of
these proteinsinIVIg-treated patientsversusnormal donors,
thus suggesting a mild reduction in the inﬂammatory status
of patients after one-year IVIg therapy. The relative ex-
pression ratios of these inﬂammatory biomarkers were not
statistically signiﬁcant in the comparison of naive versus
IVIg-treated patients (Table 3). Collectively, these data
indicate that in naive CVID patients there is a smouldering
inﬂammation, which is attenuated, but not abolished, after
one-year therapy.
3.3. Validation Analysis of Clusterin Expression in CVID.
Three diﬀerent protein spots (1812, 1831 and 1844), iden-
tiﬁed as clusterin/ApoJ, were downrepresented in the serum
of naive patients, compared to healthy donors (Table 3).
The clusterin/ApoJ proteins, encoded by the CLU gene, are
produced as a variety of intracellular and secreted isoforms,
which are associated with systemic and cellular functions
[37–39]. Clusterin/ApoJ protein function was originally
associated with inhibition of complement cascade, inﬂam-
mation, and autoimmunity;its involvement inapoptosis and
DNA repair allows also to predict a role of CLU gene in
human cancer [37–39]. In the liver, the secreted form of
clusterin/ApoJ,sCLU,isproducedfollowingalcohol-induced
liver injuries [40] and following LPS, tumour necrosis factor,6 Journal of Biomedicine and Biotechnology
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or interleukin-1 stimulation [41]. Interestingly, clusterin ex-
pression is downregulated in rheumatoid arthritis [42]. In
two out of the three patients evaluated by 2D-DIGE, IVIg
treatment resulted in a normalization of the relative abun-
dance of these spots (1812, 1831, 1844), after one-year ther-
apy (Figure 2(a)).
To validate the data originating from 2D-DIGE, we used
ad i ﬀerent approach, based on western blot analysis of ad-
ditional, naive, and IVIg-treated CVID patients. In this
analysis, we included 6 sera from newly diagnosed CVID
patients (naive group), 6 sera from normal donors, and
6 sera from patients undergoing replacement therapy with
intravenous immunoglobulins for >5 years (IVIg group).
Clinical and laboratory data of the patients are summarised
in Table 2. Each gel was loaded with 3 randomized samples
from each of the three groups. A clusterin antibody was
used to detect clusterin by western blot analysis, while
an apolipoprotein H antibody was used for normalization
o fc l u s t e r i nl e v e l si ne a c hs a m p l e .Figure 2(b) shows that
clusterin levels in normal subjects were fairly constant,
whereas in naive patients, the majority of samples exhibited
low levels of clusterin, with the exception of a single naive
sample, showing high clusterin expression. The IVIg group
was ﬁnally characterized by good expression of clusterin in
serum.These datawere analyzed bya statistical software, and
subjected to t-test analysis to evaluate whether signiﬁcant
diﬀerences were occurring among the three groups. As
shown in Figure 2(c), the analysis conﬁrmed a narrow range
for clusterin expression in the serum of normal donors;
clusterin expression in the naive group showed a strong
enrichment in low-expressing serum samples, highlighting
a signiﬁcant statistical value, compared to controls (P =
0.05), despite the single highly expressing sample. In the
IVIg group, a narrower distribution of samples and lack
of samples with low clusterin expression can be observed,
revealing a statistically relevant diﬀerence with respect to
the naive group (P = 0.04); ﬁnally, the IVIg versus normal
donor comparison (P = 0.26) does not show signiﬁcant
diﬀerences. These results conﬁrmed the downregulation of
clusterin expression in naive patients; in addition, they
conﬁrm the trend, observed following 2D-DIGE analysis,
in restoring clusterin expression in IVIg-treated patients.
One of the diﬃculties encountered in the study had to
face a slow recruitment rate of naive patients, which is an
obvious consequence of the low prevalence of CVID. Thus,
further studies on larger collections of serum samples from
matched,naive,andIVIg-treated patientswillberequiredfor
a completeevaluationofclusterin expression and correlation
analyses with disease progression and therapeutic eﬃcacy.
Since CVID actually spans over diﬀerent primary immun-
odeﬁciencies, systematic proteomic approaches on a wide
array of aﬀected patients may give relevant contributions for
the assessment of the expression signatures characterizing
such heterogeneous disorders. The availability of large
datasets of diﬀerential expression for a panel of serum
proteins, including clusterin, may indeed contribute to the
accuratestratiﬁcation of individual patients,accordingto the
peculiar features of the primary immunodeﬁciency aﬀecting
them.
3.4. Human IgGs Increase CLU Gene Expression in Human
Hepatocyte Cell Line HuH7. Data reported above suggested
that the diﬀerentially expressed proteins in serum from
CVID patients are derived from peripheral organs, mostly
from liver. It seemed therefore of interest to develop a model
system for in vitro analysis, based on human hepatocytes, to
clarify the potential role of immunoglobulins in modulating
the expression of the genes, whose products were altered
in CVID. To this aim, we ﬁrstly adapted cultures of the
human hepatocyte line HuH7, to grow under conditions
lacking serum proteins, by gradual deprivation from bovine
serum. The presence of growth factors necessary for cell
survival and proliferation in culture was insured by the
gradual adaptation of these cells to low-protein medium,
with a deﬁned composition of trophic factors (Opti-MEM).
Afterstabilizationundernovelcultureconditions,wedidnot
observe alterations in the proliferation of adapted cultures
(data not shown). Adapted HuH7 cultures were then treated
with bovine serum albumin or human IgG, at protein
concentrations comparable to those of Ig present in the
circulating blood (0.5% w/v). The relative expression of
mRNAs for clusterin was evaluated by quantitative real-
time PCR experiments. Apolipoprotein H transcript levels
were measured as an additional target in real-time PCR
experiments, being thisgene unregulated in CVID.As shown
in Figure 3, the levels of CLU transcripts were increased
(about 40%) in cells treated with immunoglobulins, com-
pared to untreated cells (P = 0.0001) or those treated
with BSA (P = 0.0003). By contrast, norelevant changes
in mRNA expression were observed for APOH transcripts.
These ﬁndings suggest that human immunoglobulins exert
a modulating activity on the expression of CLU gene in
vitro. This is in agreement with what is observed in CVID
patients, in which lower expression of clusterin correlates to
the naive status (low IgG), while a trend towards normalized
levels of circulating clusterin was associated with increased
levels of circulating IgG in patients subjected to replacement
therapy.
The cohort of subjects enrolled in this study was entirely
made of CVID patients receiving IgG administration by
intravenous route. However, IgG replacement therapy can
also be carried out via subcutaneous route of administration
to guarantee the quality of life of patients; in fact, home
subcutaneous IgG therapy can be considered a valid option
for many of them. Subcutaneous administration of IgG is
also a successful approach in most patients with previous
adverse reactions to IVIg (23). Further studies on larger
cohorts of patients subjected to IgG treatments, both by
intravenousandsubcutaneousadministrations areneededto
clarify whether clusterin can be considered a biomarker of
eﬃcacy for IgG treatments in CVID.
The ability of immunoglobulins to aﬀect CLU gene ex-
pression may account on potential mechanisms based on Fc
receptors to transduce signals upon binding to their ligands.
In addition to canonical Fcγ receptors expressed by immune
cells, several organs (including placenta, intestine, kidney,
lung, and liver) actually express the FCRN gene encoding for
the neonatal Fc receptor, FcRn [43]. Besides its involvement
in the transfer of maternal IgG to the foetus or neonate,8 Journal of Biomedicine and Biotechnology
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Figure 2: Clusterin expression in CVID. (a) The panel shows the graphic output of DeCyder software (BVA module) for spots 1812, 1831
and 1844, further identiﬁed as clusterin. The line connecting normal donors (pools P1 and P2), naive patients (N1–N3), and IVIg-treated
patients (T1–T3) in each of the panels represents average levels of the corresponding protein spot. The lines connecting naive samples to
the corresponding IVIg-treated samples denote the change in protein expression after one-year substitutive therapy for each of the three
patients. (b) Western blot analysis of clusterin in serum samples from normal donors, naive, and IVIg-treated patients. The experiment
was performed on individual serum samples from normal donors and newly enrolled, naive and IVIg-treated patients. Each gel was loaded
with serum samples from three healthy controls, three naive patients, and three IVIg-treated individuals for >5 years. The ﬁlters were ﬁrst
incubated with clusterin antibodies, then with an apolipoprotein H antibody for individual normalization of protein contents. (c) The
normal serum with highest normalized expression of clusterin was set to 1, for relative analysis of normalized clusterin expression in the
samples loaded on the western blot of Figure 2(b). The data were then used to build the shown box plot. The bottom and top of each box
represent the 25th and 75th percentile, respectively; the thick band inside each box shows the 50th percentile (the median). The ends of
the whiskers represent the minimum and maximum values of each group of data. The brackets indicate the statistical comparisons between
groups with the corresponding P values.Journal of Biomedicine and Biotechnology 9
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Figure 3: Real-time PCR analysis of clusterin transcript expression
in HuH7 cells treated with immunoglobulins. The chart shows
the expression of apolipoprotein H (APOH)o rc l u s t e r i n( CLU)
transcripts in HuH7 cells adapted to culture in Opti-MEM (OM:
black bars), or treated with immunoglobulins (Ig: white bars) or
bovine serum albumin (BSA: gray bars). The bars indicate the
averageexpression levels and the observed standard deviations.The
expression levels of CLU or APOH transcripts were normalized to
β-actin mRNA levels.
FcRnactsasahomeostaticreceptorforserumstabilizationof
IgGinadults.Recently,aninverse correlationbetweenFCRN
mRNAexpressioninperipheralbloodmononuclearcellsand
the extent of bronchiectasis in CVID has been demonstrated
[44]. These authors highlighted a faster decline in serum
IgG concentration during the 2nd week after IVIg infusion
in patients with lower FCRN mRNA level [44]. Whether
proper regulation of gene expression by circulating IgG may
be aﬀe c t e di nC V I D ,a n dw h e t h e ra l t e r e df u n c t i o no fF c R n
receptor may contribute to the disease may be an emerging
scenario in CVID.
4.Conclusions
A selective pattern of protein expression is represented in
serum of naive patients aﬀected by common variable im-
munodeﬁciency. Among the diﬀerentially expressed pro-
teins, Clusterin/ApoJ may constitute a potential biomarker
in CVID, since it is downregulated in the serum of most
CVID patients, and its levels are close to those showed by
normal subjects, in patients undergoing IVIg replacement
therapy. These results prompted us to set-up and analyze
a cellular model, based on the human hepatocyte cell line
HuH7adapted toserum-free conditions, toevaluatewhether
IgG stimulation may contribute to CLU gene regulation.
Our results suggest that CLU gene transcripts are upreg-
ulated by IgG. These results allow to hypothesize that a
signal transduction mechanism, based on the neonatal Fc
immunoglobulin receptor, may be involved in the observed
regulations on CLU gene and its products.
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